Home>REGULATORY

Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015(Sep.26.2017)
By Reiji Anasako
The pharma industry has seen floundering sales of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in Japan ever since their launch a few years ago. Now with recent statistics based on a national insurance claim database, dubbed NDB, it was revealed that doctors were indeed shying away from prescribing these medicines in the elderly age 75 and older amid swirling side effect concerns over the class ...
(LOG IN FOR FULL STORY)
The pharma industry has seen floundering sales of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in Japan ever since their launch a few years ago. Now with recent statistics based on a national insurance claim database, dubbed NDB, it was revealed that doctors were indeed shying away from prescribing these medicines in the elderly age 75 and older amid swirling side effect concerns over the class ...
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR Apr.20
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official Apr.19
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab Apr.17
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey Apr.17
-
Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
Apr.17